Navigation Links
Cytokinetics Announces Non-clinical Data to be Presented at the,2007 AACR Annual Meeting

7452, a novel small molecule cardiac myosin activator, is anticipated to enter Phase II clinical trials for the treatment of heart failure in early 2007. Under a strategic alliance established in 2006, Cytokinetics and Amgen will conduct research with activators of cardiac myosin in order to identify potential treatments for patients with heart failure. Amgen has obtained an option for the joint development and commercialization of CK-1827452 exercisable during a defined period, the ending of which is dependent on Cytokinetics' conduct of further clinical trials of CK-1827452. Cytokinetics' cancer program is focused to mitotic kinesins, a family of motor proteins essential to cell division. Cytokinetics is developing two novel drug candidates that have arisen from this program, ispinesib and SB-743921, each a novel inhibitor of kinesin spindle protein (KSP), a mitotic kinesin. Ispinesib has been the subject of a broad clinical trials program comprised of nine Phase II clinical trials as well as six Phase I or Ib clinical trials. Cytokinetics plans to conduct additional clinical trials with ispinesib and is conducting a Phase I/II trial of SB-743921 in non-Hodgkin's lymphoma. Under a strategic alliance established in 2001, Cytokinetics and GlaxoSmithKline (GSK) are conducting research and development activities focused towards the potential treatment of cancer. GSK has obtained an option for the joint development and commercialization of ispinesib and SB-743921, exercisable during a defined period. Cytokinetics and GSK are conducting collaborative research activities directed to the mitotic kinesin centromere-associated protein E (CENP-E). GSK-923295, a CENP-E inhibitor, is being developed under the strategic alliance by GSK; GSK is expected to begin clinical trials with GSK-923295 in 2007. All of these drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:12/24/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), ... the development of brachytherapy devices and medical isotopes ... it has filed a de novo ... for marketing clearance for its patented Y-90 RadioGel(TM) ... Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... , Dec. 23, 2014   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... Agency (EMA) of the Marketing Authorization Application (MAA) ... recently granted the company,s request for accelerated assessment, ... regulatory review time.   The MAA, ...
(Date:12/24/2014)... ALEXANDRIA, Va. , Dec. 23, 2014 /PRNewswire-USNewswire/ ... stringent diastolic blood pressure target for people with ... either moderate or high doses of statins, in ... risk management enacted by the American College of ... recommendations are reflected in the most recent changes ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... will present new data across its portfolio representing ... rare and difficult-to-treat cancers.  These results will be ... for Medical Oncology (ESMO) Congress in Milan, Italy ... http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO) "Pfizer ...
... Oct. 7 Vivaglobin® (subcutaneous immunoglobulin [IgG]) (SCIg) ... treatment-naive patients with primary immunodeficiency (PI) and may ... therapy in the newly diagnosed, according to data ... European Society for Immunodeficiencies. The study found that ...
Cached Medicine Technology:Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 2Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 3Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 4Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 5Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 6Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 7Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 8Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 9Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 10Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 11Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets 12Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin® as First-Line Therapy for Primary Immunodeficiency 2Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin® as First-Line Therapy for Primary Immunodeficiency 3Study Demonstrates Safety and Efficacy of Subcutaneous Vivaglobin® as First-Line Therapy for Primary Immunodeficiency 4
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional ... all of the models at LunaDress.co.uk come with big discounts, up ... wedding veil can turn out to be a most exciting memory ... can always bring surprise to a wedding. On the updated fashion ... choose veils for a big day . , Going out with ...
(Date:12/25/2014)... (HealthDay News) -- Among early stage breast cancer patients ... of one percent will eventually develop leukemia as a ... The finding comes from a review of more than ... and it suggests that the risk for developing treatment-related ... previously thought. "The frequency of bone marrow cancers ...
(Date:12/25/2014)... 25, 2014 “ SmileStix ” was featured ... the latest and coolest mobile applications on the iOS, Android, ... host of NewsWatch, conducted the app review and shared with ... personal stickers. , The old saying goes, “A picture says ... words that can describe a single image, because each picture ...
(Date:12/25/2014)... Parker & Sons, Inc. an industry leader ... quality regarding heating, cooling and plumbing services in the ... the “Queen of Clean” for impressive contractor services in ... over the years for providing outstanding quality customer service ... services for both homeowners and businesses. Linda Cobb, known ...
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Connie ... specialist and functional medicine advocate with 30 years of ... trial to evaluate the health benefits of dietary detoxification. ... with new participants following excellent results from test patients ... When asked to explain her interest in conducting the ...
Breaking Medicine News(10 mins):Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3
... issue of American Journal of Preventive Medicine says that there ... ,These conclusions were arrived at by researchers at ... Centers for Disease Control and Prevention. They monitored data of ... Factor Surveillance System survey. This particular survey covered 22 states ...
... appearing in the online journal Cancer says that elderly white ... to develop full blown melanoma regardless of their exposure to ... study found that women in the age group of 50 ... carcinoma or squamous cell carcinoma of the skin, had a ...
... attempt to rapidly eliminate milder strains of avian influenza virus ... been proposed to broaden the target of the European Union ... been taken by agricultural ministers of the 25 different countries ... the proposal, it was agreed to boost the currently existing ...
... into the oral HIV tests which have given false results. ... California and New York health centers. The rapid OraQuick Advance ... minutes. The test had gained popularity as blood samples are ... ,Complaints are being investigated by officials belonging to ...
... Hickok, neuroscientist, professor of cognitive sciences at the University ... The National Institute of //Deafness and Other Communication Disorders ... Health ($2.4 million for 5 years). ,This ... brain converts sound waves into meaningful language. ...
... health hospitals are flooded with patients with psychiatric disorders. The ... 12% in the past 4 years. ,This ... health facilities. ,According to the Australian Institute of ... specialized psychiatric hospitals decreased by 5%. ,But the ...
Cached Medicine News:Health News:Detection of Weak strains of bird flu virus – Target of European Unio 2Health News:$2.4 Million Grant To Unravel The Mystery Of Language Recognition. 2Health News:Community hospitals inundated with Psychiatric care cases (12%) 2
... Grade PRODUCT SPECIFICATIONS Form: Granular, free-flowing powder EEO(-m r ... Point (3%): less than or equal to 35.5C ... 80C Gel Strength (1.5%): greater than or equal ... greater than or equal to 1500 gm/cm 2 ...
... sulfate (SO 4 ) ≤ 6000 mg/kg Cation traces: ... ≤ 10 mg/kg Cr ≤ 10 mg/kg Cu ≤ ... mg/kg Mg ≤ 10 mg/kg Mn ≤ 10 mg/kg ... ≤ 10 mg/kg Zn ≤ 10 mg/kg Special ...
Application: Capable of separating DNA fragments of 50 to 1000 bp on a 3% gel Solubility: water 15 mg/mL, clear, colorless, hot Special grade: for molecular biology Suitab tst: electrophoresis te...
Inquire...
Medicine Products: